TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12944028

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: L-arginine with ISMN
Number of subjects: 14
Study: 10535435

Group type: EXPERIMENTAL
Intervention: WCH (White Coat Hypertension) group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: WCH group
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: True hypertension group
Number of subjects: 254
Study: 8671345

Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in threatened-continuing pregnancies
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in threatened-miscarriages
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in non-continuing pregnancies
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in tubal pregnancies
Number of subjects: 554

Group type: COMPARATOR
Intervention: Free beta-HCG measurement in control group (viable pregnancies)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Cut-off value for free beta-HCG
Number of subjects: 554
Study: 1930351

Group type: EXPERIMENTAL
Intervention: Garlic powder (900 mg total dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6754508

Group type: EXPERIMENTAL
Intervention: Combined frusemide (40 mg) and controlled-release potassium chloride (600 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frusemide and potassium supplements given as separate tablets
Number of subjects: 30
Study: 28587493

Group type: EXPERIMENTAL
Intervention: Bicarbonate intake
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-bicarbonate group (oxytocin stimulation)
Number of subjects: 200
Study: 27372892

Group type: EXPERIMENTAL
Intervention: Structured personalized ergonomic intervention program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (instruction sheets)
Number of subjects: 31
Study: 24611924

Group type: EXPERIMENTAL
Intervention: Alcohol misuse (AUDIT)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: SAVR-S drug misuse subscale
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: SAVR-S substance use disorder (SUD) screening
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Level of education (in model using AUDIT)
Number of subjects: 204
Study: 23200208

Group type: EXPERIMENTAL
Intervention: Disease management program (DMP) for diabetes mellitus type II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (administrative data)
Number of subjects: 0
Study: 20484446

Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate
Number of subjects: 211

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 211
Study: 17583416

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening intervention (randomized cohort of 822 men)
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Clinically diagnosed cohort (nonrandomized cohort of 947 men)
Number of subjects: 1769
Study: 15943599

Group type: EXPERIMENTAL
Intervention: AstraZeneca facemask
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Galemed facemask
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hans Rudolph facemask
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All masks
Number of subjects: 24
Study: 15293649

Group type: EXPERIMENTAL
Intervention: Multi-couple group therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Individual couple therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 42
Study: 11107366

Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 5 or 10 days (Group A)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: CVC dressing changes every 2 days (Group B)
Number of subjects: 339

Group type: COMPARATOR
Intervention: CVC dressing changes every 5 days (Group B)
Number of subjects: 339

Group type: COMPARATOR
Intervention: CVC dressing changes every 10 days (Group A)
Number of subjects: 339
Study: 9349932

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8399092

Group type: EXPERIMENTAL
Intervention: Gorging pattern (2 meals/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nibbling pattern (7 meals/d)
Number of subjects: 10
Study: 3486112

Group type: EXPERIMENTAL
Intervention: 150 micrograms T4 + 150 micrograms KI daily
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 100 micrograms T4 + 25 micrograms T3
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 200 micrograms T4
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: KI singly or in combination
Number of subjects: 108

Group type: COMPARATOR
Intervention: No KI
Number of subjects: 108
Study: 28697926

Group type: EXPERIMENTAL
Intervention: Health Literacy (HL) - assessed with the Short Assessment of Health Literacy for Spanish-speaking Adults questionnaire
Number of subjects: 556
Study: 26695864

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24765827

Group type: EXPERIMENTAL
Intervention: Antibiotic+steroid irrigation of the middle ear
Number of subjects: 100

Group type: COMPARATOR
Intervention: Self-administration of the same drops with systemic antibiotics
Number of subjects: 100
Study: 22809999

Group type: EXPERIMENTAL
Intervention: Aquatic Group (AG)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Floor Group (FG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 42
Study: 20430241

Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavioral therapy (T-CBT) for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 53
Study: 18227541

Group type: EXPERIMENTAL
Intervention: Postchemoradiation MR imaging
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Morphologic MR imaging criteria
Number of subjects: 64

Group type: COMPARATOR
Intervention: Subjective criteria
Number of subjects: 64
Study: 15813663

Group type: EXPERIMENTAL
Intervention: Azithromycin 500mg twice weekly for 6 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual medications
Number of subjects: 11
Study: 12878614

Group type: EXPERIMENTAL
Intervention: 0.1 MAC sevoflurane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.2 MAC sevoflurane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.3 MAC sevoflurane
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0 MAC sevoflurane (control)
Number of subjects: 6
Study: 9872190

Group type: EXPERIMENTAL
Intervention: Outpatient hydration protocol (1,000 mL clear liquid over 10 h followed by 6 h of IV hydration at 300 mL/h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Overnight IV hydration (0.45 normal saline solution at 75 mL/h for 12 h precatheterization and postcatheterization)
Number of subjects: 36
Study: 7635723

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Self-relaxation
Number of subjects: 25
Study: 2198156

Group type: EXPERIMENTAL
Intervention: Pirazolac
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 160
Study: 320957

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (mean serum lithium level, 0.9 mEq/liter)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29559428

Group type: EXPERIMENTAL
Intervention: Mobile phone-based blood glucose management system (GDm-health)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard clinic care
Number of subjects: 203
Study: 26098920

Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise and conventional physiotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 61
Study: 24822382

Group type: EXPERIMENTAL
Intervention: Two-layer compression stockings
Number of subjects: 454

Group type: COMPARATOR
Intervention: Four-layer bandages
Number of subjects: 454
Study: 22550848

Group type: EXPERIMENTAL
Intervention: Breathing meditation intervention (n = 30), practiced every morning for 4 weeks.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (non-meditation, n = 28), normal activities.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Breathing meditation intervention (n = 30).
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (non-meditation, n = 28).
Number of subjects: 58
Study: 20610595

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 28
Study: 17327863

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (OF-IN)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Synbiotic combinations
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 53
Study: 16117981

Group type: EXPERIMENTAL
Intervention: Combined treatment of infrared photocoagulation (IRP) and oral micronized purified flavonoid fraction (MPFF)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Oral micronized purified flavonoid fraction (MPFF) alone
Number of subjects: 351

Group type: COMPARATOR
Intervention: Infrared photocoagulation (IRP) alone
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Combined treatment of MPFF and IRP
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Follow-up for 90 days
Number of subjects: 351
Study: 12023410

Group type: EXPERIMENTAL
Intervention: Donepezil (5 or 10 mg per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10078887

Group type: EXPERIMENTAL
Intervention: Outpatient CGA consultation coupled with an adherence intervention
Number of subjects: 363
Study: 8625179

Group type: EXPERIMENTAL
Intervention: Oral combination antiemetic regimen of metoclopramide (3 mg/kg x 2 then 2 mg/kg x 2 or 4 doses), dexamethasone (20 mg), and diphenhydramine (50 mg x 2 or 3 doses)
Number of subjects: 52
Study: 2185156

Group type: EXPERIMENTAL
Intervention: Short course ceftriaxone (100 mg/kg on days one and two and 60 mg/kg thereafter for four, six, or seven days)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Full course ceftriaxone (eight, 12, or 14 days)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Secondary exclusion group (20 culture-positive of the 27 children excluded)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: All patients (both groups)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Full course therapy
Number of subjects: 119
Study: 94873

Group type: EXPERIMENTAL
Intervention: Micristin (401 patients)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo (401 patients)
Number of subjects: 802
Study: 6660438

Group type: EXPERIMENTAL
Intervention: Theo-Dur (sustained-release preparation of theophylline), given twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nuelin (conventional fast-release preparation), given three times daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Theo-Dur (sustained-release preparation of theophylline)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nuelin (conventional fast-release preparation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Theo-Dur and Nuelin
Number of subjects: 19
Study: 31474174

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 571

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 571
Study: 28508936

Group type: EXPERIMENTAL
Intervention: ZYAN1 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ZYAN1 300 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ZYAN1 single ascending doses (10, 25, 50, 100, 150, 200, 300 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ZYAN1 multiple doses (100, 150, 200, 300 mg every other day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ZYAN1
Number of subjects: 100
Study: 27797094

Group type: EXPERIMENTAL
Intervention: Automated syringe technique
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional loss of resistance technique
Number of subjects: 47
Study: 25110372

Group type: EXPERIMENTAL
Intervention: 16 text messages with recommendations on the management of viral infections and otitis media
Number of subjects: 977

Group type: COMPARATOR
Intervention: Traditional training (one-day workshop)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: 16 text messages
Number of subjects: 977
Study: 22754902

Group type: EXPERIMENTAL
Intervention: Syringeable paste allograft with resorbable extracellular matrix membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19896342

Group type: EXPERIMENTAL
Intervention: Acute tryptophan (TRP) depletion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 24
Study: 17572791

Group type: EXPERIMENTAL
Intervention: Social skills training for 12 weeks
Number of subjects: 101
Study: 16430123

Group type: EXPERIMENTAL
Intervention: Semi-standardised acupuncture (12 sessions)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standardised minimal acupuncture (superficial needling of at least 5 of 10 predefined points)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 270
Study: 12145771

Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lower Body Resistive Training (LBRT) 3 times/week
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole Body Resistive Training (WBRT) 3 times/week
Number of subjects: 28

Group type: COMPARATOR
Intervention: SED, LBRT, WBRT
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Men vs Women
Number of subjects: 28
Study: 9860476

Group type: EXPERIMENTAL
Intervention: Longitudinal pancreaticojejunostomy combined with local pancreatic head excision (LPJ-LPHE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Pylorus-preserving pancreatoduodenectomy (PPPD)
Number of subjects: 61
Study: 7710029

Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine (either infusion of 0.125% or top‐ups of 10 ml of 0.25%)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pethidine with intermittent Entonox
Number of subjects: 51

Group type: COMPARATOR
Intervention: Extradural bupivacaine with 2 micrograms.ml‐1 fentanyl
Number of subjects: 51

Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 51
Study: 2565997

Group type: EXPERIMENTAL
Intervention: sulphasalazine
Number of subjects: 60

Group type: COMPARATOR
Intervention: hydroxychloroquine
Number of subjects: 60
Study: 341965

Group type: EXPERIMENTAL
Intervention: Photocoagulation treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 48
Study: 30674917

Group type: EXPERIMENTAL
Intervention: MFGM isolate-supplemented experimental formula (EF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast-fed infants (BF)
Number of subjects: 0
Study: 28816169

Group type: EXPERIMENTAL
Intervention: EBRT with iridium implant (40 Gy/20 fractions + 35 Gy/48 hours)
Number of subjects: 104

Group type: COMPARATOR
Intervention: EBRT alone (66 Gy/33 fractions)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: EBRT with iridium implant
Number of subjects: 104

Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 104
Study: 24962143

Group type: EXPERIMENTAL
Intervention: Back massage for 20 minutes
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sitting position for 20 minutes (Control)
Number of subjects: 101
Study: 24016561

Group type: EXPERIMENTAL
Intervention: Batroxobin
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Batroxobin + Ginkgo Biloba Leaves Extract (EGb)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Batroxobin + EGb + Glucocorticoids
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: EGb + Glucocorticoids
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 276
Study: 21228406

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 19254484

Group type: EXPERIMENTAL
Intervention: Less intensive self-monitoring (blood glucose self-testing with patient training focused on clinician interpretation of results)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: More intensive self-monitoring (SMBG with additional training of patients in interpretation and application of results)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Standardised usual care (control group)
Number of subjects: 453
Study: 17768282

Group type: EXPERIMENTAL
Intervention: Collaborative consultative service promoting the use of titration trials and periodic monitoring during medication maintenance.
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control group (no collaborative consultative services).
Number of subjects: 377
Study: 15060236

Group type: EXPERIMENTAL
Intervention: Nutramigen (unpleasant-tasting protein hydrolysate formula)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enfamil (milk-based formula)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutramigen for 3 months and Enfamil for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alimentum (novel hydrolysate formula)
Number of subjects: 0
Study: 10989729

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 98

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 98
Study: 8632218

Group type: EXPERIMENTAL
Intervention: Vitamin A supplement (210 mumol) + Albendazole (400 mg)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Albendazole (400 mg) only
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Vitamin A supplement (210 mumol) only
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Vitamin A supplement + Albendazole (two groups)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Vitamin A supplement + Albendazole (third group)
Number of subjects: 309
Study: 1557640

Group type: EXPERIMENTAL
Intervention: Combination treatment (folinic acid 200 mg/m2 + 5-FU 370 mg/m2 IV days 1 to 5 followed by weekly 5-FU 600 mg/m2, reduced to 500 mg/m2 due to toxicity)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Monotherapy (5-FU 370 mg/m2 IV days 1 to 5 followed by weekly 5-FU 600 mg/m2)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination treatment (initial dosage of 5-FU 600 mg/m2)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination treatment (after reduction of 5-FU dosage to 500 mg/m2)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 135
Study: 3926508

Group type: EXPERIMENTAL
Intervention: Indomethacin, 150 mg daily for 3 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31107913

Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) IVR (8-10 mg/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tenofovir/Levonorgestrel (TFV/LNG) IVR (20 ug/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo IVR
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All IVR users
Number of subjects: 51
Study: 28421299

Group type: EXPERIMENTAL
Intervention: Sodium polystyrene sulfonate (SPS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium polystyrene sulfonate (CPS)
Number of subjects: 20
Study: 28594772

Group type: EXPERIMENTAL
Intervention: Blood glucose testing four times a day
Number of subjects: 286

Group type: COMPARATOR
Intervention: Blood glucose testing every other day
Number of subjects: 286
Study: 25439432

Group type: EXPERIMENTAL
Intervention: Overnight orthokeratology (OK) contact lens wear
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional rigid gas‐permeable (GP) lenses
Number of subjects: 26
Study: 24186588

Group type: EXPERIMENTAL
Intervention: Hand-held gamma probe (Navigator GPS) used intraoperatively in Group I (Nav)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No gamma probe used in Group II
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 21929562

Group type: EXPERIMENTAL
Intervention: PLC 1 g/day
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: PLC 2 g/day
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 18241707

Group type: EXPERIMENTAL
Intervention: Intracapsular tonsillectomy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Subcapsular tonsillectomy
Number of subjects: 69
Study: 16685543

Group type: EXPERIMENTAL
Intervention: Rapid Rhino nasal tampons
Number of subjects: 42

Group type: COMPARATOR
Intervention: Merocel nasal tampons
Number of subjects: 42
Study: 14580025

Group type: EXPERIMENTAL
Intervention: Er:YAG laser ablation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acid-etched
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acid-etched then laser-ablated
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laser-ablated then acid-etched
Number of subjects: 40
Study: 10914843

Group type: EXPERIMENTAL
Intervention: Prednisone (4.37 mg daily)
Number of subjects: 824

Group type: COMPARATOR
Intervention: No prednisone
Number of subjects: 824
Study: 8838183

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-clindamycin (Pyr-Cm)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Pyrimethamine-sulfadiazine (Pyr-Sdz)
Number of subjects: 299
Study: 1428189

Group type: EXPERIMENTAL
Intervention: Loracarbef (200 mg capsule twice daily or 15 mg/kg/day oral suspension in two divided doses up to a maximum of 375 mg/day)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Penicillin V (250 mg capsule four times daily or 20 mg/kg/day suspension in four divided doses up to a maximum of 500 mg/day)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 344